- Home
- FOLD
as 11-12-2025 3:43pm EST
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.5B | IPO Year: | 2007 |
| Target Price: | $30.29 | AVG Volume (30 days): | 5.0M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.51 - $10.83 | Next Earning Date: | 11-04-2025 |
| Revenue: | $598,704,000 | Revenue Growth: | 21.28% |
| Revenue Growth (this year): | 21.12% | Revenue Growth (next year): | 21.23% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Clark David Michael | FOLD | Chief People Officer | Nov 4 '25 | Sell | $9.51 | 25,643 | $243,859.80 | 322,618 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
MT Newswires
5 months ago
Amicus Therapeutics Says Japan Approval Received for Late-Onset Pompe Disease Treatment
GlobeNewswire
5 months ago
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Insider Monkey
5 months ago
Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment
Zacks
5 months ago
New Strong Sell Stocks for June 3rd
GlobeNewswire
5 months ago
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
GlobeNewswire
5 months ago
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
Simply Wall St.
6 months ago
3 High Growth Tech Stocks In The US Market
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.